From: Depression risk among breast cancer survivors: a nationwide cohort study in South Korea
 | Age group |  | Subjects, N | Case, N | Duration, PY | Incidence rate (per 1,000 PY) | sHR (95% CI) | ||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | |||||||
During the first year post-diagnosis | |||||||||
 | All ages | Control | 99,834 | 2,826 | 98,440.30 | 28.7 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 59,340 | 5,304 | 55,866.60 | 94.9 | 3.22 (3.08–3.37) | 3.23 (3.09–3.38) | 3.23 (3.08–3.37) |
 | Age ≤ 50 | Control | 49,312 | 952 | 48,849.20 | 19.5 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 29,922 | 2,567 | 28,275.50 | 90.8 | 4.51 (4.19–4.84) | 4.51 (4.19–4.85) | 4.51 (4.19–4.85) |
 | Age > 50 | Control | 50,522 | 1,874 | 49,591.20 | 37.8 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 29,418 | 2,737 | 27,591.10 | 99.2 | 2.57 (2.42–2.72) | 2.57 (2.43–2.72) | 2.56 (2.42–2.71) |
 | P for interaction |  |  |  |  | < 0.001 | < 0.001 | < 0.001 | |
1-year landmark | |||||||||
 | All ages | Control | 97,006 | 15,870 | 556,638.2 | 28.5 | 1 (ref.) | 1 (ref.) | 1 (ref .) |
 |  | Breast cancer | 53,879 | 9,188 | 301,244.6 | 30.5 | 1.04 (1.01–1.07) | 1.04 (1.02–1.07) | 1.04 (1.01–1.07) |
 | Age ≤ 50 | Control | 48,359 | 6,087 | 284,242 | 21.4 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 27,293 | 3,949 | 155,560.4 | 25.4 | 1.15 (1.11–1.20) | 1.15 (1.11–1.2) | 1.16 (1.11–1.2) |
 | Age > 50 | Control | 48,647 | 9,783 | 272,396.2 | 35.9 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 26,586 | 5,239 | 145,684.2 | 36 | 0.97 (0.94–1.01) | 0.98 (0.94–1.01) | 0.97 (0.94-1.00) |
 | P for interaction |  |  |  |  | < 0.001 | < 0.001 | < 0.001 | |
3-year landmark | |||||||||
 | All ages | Control | 91,513 | 10,458 | 368,191.9 | 28.4 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 49,209 | 5,310 | 198,522.7 | 26.7 | 0.93 (0.90–0.96) | 0.93 (0.90–0.96) | 0.93 (0.90–0.96) |
 | Age ≤ 50 | Control | 46,394 | 4,135 | 189,479.3 | 21.8 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 25,241 | 2,251 | 103,251.1 | 21.8 | 0.99 (0.90–1.04) | 0.99 (0.94–1.04) | 0.99 (0.94–1.04) |
 | Age > 50 | Control | 45,119 | 6,323 | 178,712.6 | 35.3 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 23,968 | 3,059 | 95,271.6 | 32.1 | 0.89 (0.85–0.93) | 0.89 (0.85–0.93) | 0.89 (0.85–0.93) |
 | P for interaction |  |  |  |  | 0.002 | 0.003 | 0.002 | |
5-year landmark | |||||||||
 | All ages | Control | 76,469 | 5,521 | 194,148.2 | 28.4 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 40,972 | 2,802 | 105,234 | 26.6 | 0.92 (0.88–0.97) | 0.93 (0.89–0.97) | 0.93 (0.88–0.97) |
 | Age ≤ 50 | Control | 39,485 | 2,232 | 100,639.4 | 22.2 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 21,342 | 1,163 | 55,131.1 | 21.1 | 0.98 (0.87–1.01) | 0.94 (0.87–1.01) | 0.94 (0.87–1.01) |
 | Age > 50 | Control | 36,984 | 3,289 | 93,508.8 | 35.2 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
 |  | Breast cancer | 19,630 | 1,639 | 50,102.9 | 32.7 | 0.92 (0.86–0.97) | 0.92 (0.88–0.98) | 0.92 (0.86–0.97) |
 | P for interaction |  |  |  |  | 0.63 | 0.73 | 0.66 |